Valuation
- Market cap
- 53,476,000
- Revenue TTM
- $0
- Net income TTM
- $-149,340,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 298,312
- Avg volume
- 417,278
- Day's range
- $0.84 – $0.90
- Shares out
- 61,922,000
- Stochastic %K
- 20%
- Beta
- 1.27
- Analysts
- Hold
- Price target
- $2.50
Company profile
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary...
Show more
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 481 6770
- Website
- https://pliantrx.com
- Address
- 331 Oyster Point Boulevard, South San Francisco, United States
Latest news
No headlines yet.
